

LFA-1

BI-1950

Table of contents

Summary	2
Chemical Structure.....	2
Highlights.....	3
Target information.....	3
<i>In vitro</i> activity.....	4
<i>In vitro</i> DMPK and CMC parameters	4
<i>In vivo</i> DMPK parameters.....	5
<i>In vivo</i> pharmacology	5
Selectivity.....	5
Negative control.....	6
Co-crystal structure of the BI probe compound and the target protein.....	6
Supplementary data	6
References.....	7

Summary

BI-1950 is a highly potent inhibitor of LFA-1 and an excellent molecule for testing biological hypotheses *in vitro* and *in vivo*.

Chemical Structure




Figure 1: 2D structure of BI-1950, a LFA1 antagonist




Figure 2: 3D conformation of BI-1950

Highlights

BI-1950 is a highly potent and selective lymphocyte function-associated antigen-1 (LFA-1) inhibitor. It prevents the binding of ICAM-1 to LFA-1 and, as a result, inhibits the production of IL-2 as demonstrated in human whole blood and PBMCs. BI-1950 shows an attractive DMPK profile and was tested *in vivo* in a proof-of-concept mouse model for delayed-type hypersensitivity, where it inhibited swelling in a dose-dependent manner and showed full efficacy at an oral dose of 3 mg/kg.

Target information

The integrin LFA-1 (lymphocyte function-associated antigen-1) is a receptor present on lymphocytes that plays, together with its major ligand ICAM-1 (intercellular adhesion molecule 1), an important role in immune cell function^{1,3,4}.



Figure 3: X-Ray structure of LFA-1 with an analogue of BI-1950 (solved at Boehringer Ingelheim)

In vitro activity

It inhibits the binding of LFA-1 to ICAM-1 with a K_D value of 9 nM and the production of IL-2 in human PBMC and whole blood with an IC_{50} value of 3 nM and 120 nM, respectively.

PROBE NAME / NEGATIVE CONTROL	BI-1950	BI-9446
MW [Da, free base] ^a	646.5	602.5
Inhibition of LFA-1 binding to ICAM-1 K_D [nM] ^b	9	>1,000
Inhibition of SEB-induced production of IL-2 in human PBMC IC_{50} [nM] ^c	3	>1,000
Inhibition of SEB-induced production of IL-2 in human whole blood IC_{50} [nM] ^c	120	n.a.

^a For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs

^b Binding assay

^c SEB: staphylococcal enterotoxin B

In vitro DMPK and CMC parameters

PROBE NAME / NEGATIVE CONTROL	BI-1950	BI-9446
logD @ pH 11	4.7	5.9
Solubility @ pH 6.8 [μ g/mL]	1.2	0.1
Caco-2 permeability AB @ pH 7.4 [$\times 10^{-6}$ cm/s]	13	n.a.
Caco-2 efflux ratio	2	n.a.
Microsomal stability (human/mouse/rat) [% Q_H]	13 / 12 / 6	n.a.
Plasma Protein Binding (human/mouse/dog) [%]	99.6 / 99.7 / 99.9	n.a.
hERG [inh. % @ 1 μ M]	6.7	n.a.

In vivo DMPK parameters

PROBE NAME / NEGATIVE CONTROL	BI-1950	
Species	mouse	rat
Clearance [% Q _H] ^a	5	1.1
V _{ss} [L/kg] ^a	1.3	2.7
Mean residence time after i.v. dose [h] ^a	5	6.5
F [%] ^b	84	21

^ai.v. dose: 1 mg/kg

^bp.o. dose: 10 mg/kg

In vivo pharmacology

BI-1950 shows an attractive DMPK profile and was tested in a proof-of-concept LFA-1 model *in vivo*. As BI-1950 demonstrates greater than 250-fold selectivity for human over mouse LFA-1 as assessed in paired assays that measure the inhibition of IL-2 production in SEB-stimulated human PBMC and mouse splenocytes (SEB: staphylococcal enterotoxin B), a *trans vivo* model for delayed type hypersensitivity (DTH) in SCID mice was used⁵. After injection of human PBMCs into the footpad of SCID mice and stimulation with a specific antigen (tetanus toxoid, TT), the DTH response is quantified by measuring the footpad swelling. BI-1950 inhibited swelling in a dose dependent manner and showed full efficacy at a dose of 3 mg/kg *p.o.*

Selectivity

In an external selectivity screen at Eurofins SafetyScreen44™ BI-1950 hit 4/47 targets >50 % Inhibition @ 10 µM. See supplementary information for details.

BI-1950 shows > 1,000-fold selectivity against the most closely related b2-integrin Mac-1 and b1-integrin function.

The selectivity of the compound against a selection of 315 GPCR targets was also tested simultaneously and in parallel using the PRESTO-TANGO selectivity screen provided by the Psychoactive Drug Screening Program (PDSP)⁹. No significant inhibition (modulation) observed for any of the 315 GPCRs tested @ 10 µM.

SELECTIVITY DATA AVAILABLE	BI-1950	BI-9446
SafetyScreen44™ with kind support of  eurofins	Yes	Yes
PRESTO-TANGO (PDSP)	Yes	Yes

Invitrogen®	No	No
DiscoverX®	No	No
Dundee	No	No

Negative control

The close analog BI-9446 can be used as negative control for *in vitro* studies with much weaker affinity to LFA-1 ($> 1\mu\text{M}$).




Figure 4: Chemical structure of the negative control BI-9446

Co-crystal structure of the BI probe compound and the target protein

No Xray structure is available for BI-1950 but for the structurally related compound (**17d** in *J. Med. Chem.* **2004**, 47, 5356)².

Supplementary data

2-D structure files can be downloaded free of charge from [openMe](https://openme.boehringer-ingenheim.com).

References

1. Kelly T. A., Jeanfavre D. D., McNeil D. W., Woska J. R. Jr, Reilly P. L., Mainolfi E. A., Kishimoto K. M., Nabozny G. H., Zinter R., Bormann B. J., Rothlein R. Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion *J. Immunol.* **1999**, 163, 5173. [PubMed](#).
2. Wu J. P., Emeigh J., Gao D. A., Goldberg D. R., Kuzmich D., Miao C., Potocki I., Qian K. C., Sorcek R. J., Jeanfavre D. D., Kishimoto K., Mainolfi E. A., Nabozny G. Jr., Peng C., Reilly P., Rothlein R., Sellati R. H., Woska J. R. Jr., Chen S., Gunn J. A., O'Brien D., Norris S. H., Kelly T. A. Second-Generation Lymphocyte Function Associated Antigen-1 Inhibitors: 1*H*-Imidazo[1,2- α]imidazol-2-one Derivatives *J. Med. Chem.* **2004**, 47, 5356. [DOI: 10.1021/jm049657b](#), [PubMed](#).
3. Winkquist R. J., Desai S., Fogal S., Haynes N. A., Nabozny G. H., Reilly P. L., Souza D., Panzenbeck M. The role of leukocyte function-associated antigen-1 in animal models of inflammation *Eur. J. Pharmacol.* **2001**, 429, 297. [DOI: 10.1016/S0014-2999\(01\)01328-0](#), [PubMed](#).
4. Panzenbeck M. J., Jeanfavre D. D., Kelly T. A., Lemieux R., Nabozny G., Reilly P. L., Desai S. An orally active, primate selective antagonist of LFA-1 inhibits delayed-type hypersensitivity in a humanized-mouse model *Eur. J. Pharmacol.* **2006**, 534, 233. [DOI: 10.1016/j.ejphar.2006.01.004](#), [PubMed](#).
5. Carrodeguas L., Orosz C. G., Waldmann W. J., Sedmak D. D., Adams P. W., VanBuskirk A. M. Trans vivo Analysis of Human Delayed-Type Hypersensitivity Reactivity *Human Immunology* **1999**, 60, 641-651. [DOI: 10.1016/S0198-8859\(99\)00002-6](#), [PubMed](#).
6. Frutos R. R., Johnson M. Regiocontrolled synthesis of highly-functionalized fused imidazoles: a novel synthesis of second generation LFA-1 inhibitors *Tetrahedron Lett.* **2003**, 44, 6509. [DOI: 10.1016/S0040-4039\(03\)01535-1](#).
7. Wang X. J., Xu Y., Zhang L., Krishnamurthy D., Wirth T., Nicola T., Senanayake C. H. Efficient Synthesis of a Small Molecule, Nonpeptide Inhibitor of LFA-1 *Org. Lett.* **2010**, 12, 4412. [DOI: 10.1021/ol101960x](#), [PubMed](#).
8. Wang X. J., Frutos R. P., Zhang L., Sun X., Xu Y., Wirth T., Nicola T., Nummy L. J., Krishnamurthy D., Busacca C. A., Yee N., Senanayake C. H. Asymmetric Synthesis of LFA-1 Inhibitor BIRT2584 on Metric Ton Scale *Org. Process Res. Dev.* **2011**, 15, 1185. [DOI: 10.1021/op200175t](#).
9. Kroeze W. K., Sassano M. F., Huang XP., Lansu K., McCorvy J. D., Giguère P. M., Sciaky N., Roth B. L. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome *Nat Struct Mol Biol.* **2015**, 22(5):362-9. [DOI: 10.1038/nsmb.3014](#), [PubMed](#).